Edict Acquisition (Tables) (Edict Acquisition [Member])

12 Months Ended

Dec. 31, 2013

Edict Acquisition [Member]

Business Acquisition [Line Items]

Schedule of Business Combination, Consideration Transferred

The acquisition-date fair value of the consideration transferred consisted of the following items ($ in thousands):

Cash paid for equity		$20,659
Contingent purchase price liabilities	11,641		(1)
Cash paid for assumed indebtedness	4,300
Total consideration		$36,600

(1) Contingent purchase price liabilities represent subsequent milestone payments related to successful FDA inspection of the Par Formulations manufacturing facility and ANDA filings.  All contingent purchase price liabilities were paid in full within 18 months of the acquisition date.

Schedule of Business Combination, Allocation of Assets and Liabilities

The purchase price of Par Formulations was allocated to the following assets and liabilities prior to the Merger ($ in thousands):

	As of  February 17, 2012
Cash and cash equivalents	$	273
Inventories	192
Prepaid expenses and other current assets	1,143
Property, plant and equipment	5,370
Intangible assets	1,850
Total identifiable assets	8,828
Accounts payable	995
Accrued expenses and other current liabilities	200
Deferred tax liabilities	938
Total liabilities assumed	2,133
Net identifiable assets acquired	6,695
Goodwill	29,905
Net assets acquired	$	36,600

Schedule of Supplemental Pro Forma Information

The pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized had the Edict Acquisition been consummated during the periods for which pro forma information is presented, or is it intended to be a projection of future results or trends.

	December 31,			December 31,
(amounts in thousands)	2012			2011
Total revenues		$1,050,007			$926,138
Loss from continuing operations		($9,707	)		($50,476	)